Natus Medical launches EMG and EMEA/APAC EEG advisory boards
Natus Medical Incorporated has expanded its global clinical engagement with the launch of an inaugural Global EMG Advisory Board and a first Europe, Middle East, Africa, and Asia-Pacific EEG Advisory Board. Both bodies met in early November at the company's offices in Mogliano Veneto, Italy, bringing together neurologists, clinical neurophysiologists, epileptologists, and neuromuscular specialists from across three regions.
The meetings follow Natus's establishment of a Global EEG Advisory Board in May this year and a separate Americas EEG Advisory Board earlier in 2026. The two new boards extend that framework to cover electrodiagnostic medicine and to incorporate clinical perspectives from EMEA and Asia-Pacific markets.
The boards in detail
The Global EMG Advisory Board is chaired by Dr Holly Lorigan, Division Head of Neuromuscular Neurology and Director of the Clinical Neurophysiology and EMG Laboratory at Henry Ford Health in the United States. It draws in specialists from the United Kingdom, Finland, Norway, Denmark, and the United States, with expertise spanning EMG, nerve conduction studies, neuromuscular ultrasound, and clinical neurophysiology.
The EMEA and Asia-Pacific EEG Advisory Board is composed of clinicians from Australia, France, Malaysia, Italy, Switzerland, the United Kingdom, and the United States. Its membership covers epilepsy, neurocritical care, neonatal EEG, and advanced EEG technologies. Notably, it includes Dr Ronit Pressler from Great Ormond Street Hospital for Children in London and Dr Philippe Ryvlin from Lausanne University Hospital, both prominent figures in European epilepsy research.
Natus said outputs from both meetings will feed into its strategic priorities across product development, clinical evidence generation, workflow improvements, and global medical education. The company did not disclose specific product timelines, development programmes, or financial commitments tied to the advisory structure.
Chief executive Chris Landon said bringing together clinicians from around the world allows the company to "look beyond individual technologies and better understand the evolving needs of patients, healthcare providers, and health systems."
Market context
Neurodiagnostics is a relatively specialised segment within the broader medical-devices market, but it is attracting increasing attention as AI-assisted signal analysis matures. EEG and EMG platforms are prime candidates for machine-learning integration, particularly for seizure detection, automated spike classification, and remote monitoring in neurocritical care settings. Several university-spinout and digital-health companies are developing software layers that sit atop established hardware, intensifying competitive pressure on incumbent device makers.
Natus, which positions itself as a full-service provider of neurodiagnostic hardware, software, and education, appears to be using its advisory board structure partly to defend that integrated position by anchoring future product decisions to clinical consensus rather than technology-push alone. The geographic spread of both boards, spanning five continents, also suggests a deliberate effort to tailor workflows to the regulatory and reimbursement realities of non-US markets, where EEG and EMG practice can differ substantially from American protocols.
Near-term milestones to watch include any formal product announcements that cite advisory board input, and whether Natus publishes white papers or clinical guidance documents as tangible outputs from the November meetings.